Osteoporosis in men: epidemiology and treatment with denosumab

Kristel M Sidlauskas, Emily E Sutton, Michael A Biddle Albany College of Pharmacy and Health Sciences-Vermont Campus, Colchester, VT, USA Abstract: Osteoporosis is a major public health care concern. Although often described as a disease affecting postmenopausal women, researchers and clinicians ha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sidlauskas KM, Sutton EE, Biddle MA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Denosumab Osteoporosis Men Treatment Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/d7f2f454f05a4b7caa35297f994f5d0d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d7f2f454f05a4b7caa35297f994f5d0d
record_format	dspace
spelling	oai:doaj.org-article:d7f2f454f05a4b7caa35297f994f5d0d2021-12-02T02:48:54ZOsteoporosis in men: epidemiology and treatment with denosumab1178-1998https://doaj.org/article/d7f2f454f05a4b7caa35297f994f5d0d2014-04-01T00:00:00Zhttps://www.dovepress.com/osteoporosis-in-men-epidemiology-and-treatment-with-denosumab-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Kristel M Sidlauskas, Emily E Sutton, Michael A Biddle Albany College of Pharmacy and Health Sciences-Vermont Campus, Colchester, VT, USA Abstract: Osteoporosis is a major public health care concern. Although often described as a disease affecting postmenopausal women, researchers and clinicians have emphasized its prevalence in men in recent years. The National Osteoporosis Foundation has stated that up to 25% of men over the age of 50 years will experience a fracture due to osteoporosis. Men who suffer from a major fracture have higher mortality rates than women. Pharmacologic therapy options for treating osteoporosis are limited for men as compared with women, so each medication approved for use in this population represents an important clinical option. In September 2012, the US Food and Drug Administration approved a new indication for denosumab to increase bone mass in men with osteoporosis at high risk for fracture. Denosumab is a fully human monoclonal antibody and novel antiresorptive agent that works by binding receptor activator of nuclear factor kappa-β ligand (RANKL) and inhibiting the signaling cascade that causes osteoclast maturation, activity, and survival. Ultimately, denosumab suppresses bone turnover and increases bone mineral density in both trabecular and cortical bone. Approval for treating osteoporosis in men was based on data from the ADAMO trial which displayed efficacy in increasing bone mineral density at the lumbar spine, total hip, femoral neck, hip trochanter, and one-third radius. Studies indicate that denosumab is effective and safe, and has superior adherence rates and patient satisfaction. Although long-term data and further research on fracture reduction rates in men should be explored, at this time denosumab is one of several appropriate first-line treatment options for men with osteoporosis. Keywords: denosumab, osteoporosis, men, treatmentSidlauskas KMSutton EEBiddle MADove Medical PressarticleDenosumabOsteoporosisMenTreatmentGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 9, Pp 593-601 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Denosumab Osteoporosis Men Treatment Geriatrics RC952-954.6
spellingShingle	Denosumab Osteoporosis Men Treatment Geriatrics RC952-954.6 Sidlauskas KM Sutton EE Biddle MA Osteoporosis in men: epidemiology and treatment with denosumab
description	Kristel M Sidlauskas, Emily E Sutton, Michael A Biddle Albany College of Pharmacy and Health Sciences-Vermont Campus, Colchester, VT, USA Abstract: Osteoporosis is a major public health care concern. Although often described as a disease affecting postmenopausal women, researchers and clinicians have emphasized its prevalence in men in recent years. The National Osteoporosis Foundation has stated that up to 25% of men over the age of 50 years will experience a fracture due to osteoporosis. Men who suffer from a major fracture have higher mortality rates than women. Pharmacologic therapy options for treating osteoporosis are limited for men as compared with women, so each medication approved for use in this population represents an important clinical option. In September 2012, the US Food and Drug Administration approved a new indication for denosumab to increase bone mass in men with osteoporosis at high risk for fracture. Denosumab is a fully human monoclonal antibody and novel antiresorptive agent that works by binding receptor activator of nuclear factor kappa-β ligand (RANKL) and inhibiting the signaling cascade that causes osteoclast maturation, activity, and survival. Ultimately, denosumab suppresses bone turnover and increases bone mineral density in both trabecular and cortical bone. Approval for treating osteoporosis in men was based on data from the ADAMO trial which displayed efficacy in increasing bone mineral density at the lumbar spine, total hip, femoral neck, hip trochanter, and one-third radius. Studies indicate that denosumab is effective and safe, and has superior adherence rates and patient satisfaction. Although long-term data and further research on fracture reduction rates in men should be explored, at this time denosumab is one of several appropriate first-line treatment options for men with osteoporosis. Keywords: denosumab, osteoporosis, men, treatment
format	article
author	Sidlauskas KM Sutton EE Biddle MA
author_facet	Sidlauskas KM Sutton EE Biddle MA
author_sort	Sidlauskas KM
title	Osteoporosis in men: epidemiology and treatment with denosumab
title_short	Osteoporosis in men: epidemiology and treatment with denosumab
title_full	Osteoporosis in men: epidemiology and treatment with denosumab
title_fullStr	Osteoporosis in men: epidemiology and treatment with denosumab
title_full_unstemmed	Osteoporosis in men: epidemiology and treatment with denosumab
title_sort	osteoporosis in men: epidemiology and treatment with denosumab
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/d7f2f454f05a4b7caa35297f994f5d0d
work_keys_str_mv	AT sidlauskaskm osteoporosisinmenepidemiologyandtreatmentwithdenosumab AT suttonee osteoporosisinmenepidemiologyandtreatmentwithdenosumab AT biddlema osteoporosisinmenepidemiologyandtreatmentwithdenosumab
_version_	1718402130706956288

Osteoporosis in men: epidemiology and treatment with denosumab

Ejemplares similares